|
Zacks Bull and Bear of the Day Highlights: Canadian Solar, Corp. Executive Board, UDR, Cephalon and ASML Holding
CHICAGO--July 17 2008 -Zacks Equity Research highlights Canadian Solar (Nasdaq: CSIQ) as the Bull of the Day and The Corp. Executive Board (Nasdaq: EXBD) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on UDR, Inc. (NYSE: UDR), Cephalon, Inc. (Nasdaq: CEPH) and ASML Holding N.V. (Nasdaq: ASML).
Full analysis of all these stocks is available at http://at.zacks.com/?id=2676 .
Here is a synopsis of all five stocks:
Bull of the Day: Canadian Solar (Nasdaq: CSIQ)
CSIQ’s recent bullishness has been boosted due to improving company fundamentals and a steep rise in the price of oil. Going forward, on the back of solar panel sales growth in various global markets, extension of product lines, material cost savings through the company’s more vertically-integrated production structure, higher captive generation of solar cells, long-term supply agreements and a silicon reclamation program should, collectively, generate significant earnings growth.
Bear of the Day: The Corp. Executive Board (Nasdaq: EXBD)
Given the current operating pressures, along with ongoing concerns regarding a slowing economy, we believe the shares should trade at a discount to the peer group average. In light of these issues, we anticipate that the company’s shares will underperform the market in the near-term, and as such, we rate the shares of EXBD a Sell at this time. EXBD is scheduled to release Q2 results on July 23.
Latest Posts on the Zacks Analyst Blog:
UDR, Inc. (NYSE: UDR)
UDR is an apartment real estate investment trust (REIT) that owns, operates, acquires, develops, and renovates middle-market apartment communities. In early March, the company sold 40% of its portfolio located primarily in slower growth, lower rent, Midwestern and Southern markets. While this transaction will be dilutive in 2008, overall we like this deal as the company will improve its asset base and balance sheet.
The company will use the majority of the proceeds to acquire better assets in higher rent areas, pay down debt, buy back shares, and possibly pay a one-time special dividend. We maintain our Buy rating due to valuation and continued problems in the for-sale housing market.
Cephalon, Inc. (Nasdaq: CEPH)
The settlement of all patent infringement cases on Provigil (for psychological disorders) has been a significant positive for Cephalon. With Provigil protected from the entry of generics until October 2011, we believe that investor focus will shift towards the company's emerging oncology pipeline and muscle relaxer Amrix.
The company's agreement with the U.S. Attorney's Office in Philadelphia and the U.S. Department of Justice on investigations into its marketing and promotion practices removes a significant overhang from the shares. Nevertheless, the Federal Trade Commission's lawsuit related to the Provigil settlements remains a matter of concern. We rate the stock a Hold.
ASML Holding N.V. (Nasdaq: ASML)
ASML is the largest original equipment manufacturer (OEM) of advanced photolithography systems used within the semiconductor manufacturing industry. March quarter revenue and EPS outperformed consensus estimates. The company has the leading position in the next-generation immersion lithography tools, which will lead to long-term growth.
Flash memory makers are ramping chip production in the 50 nanometer (nm) range and most other semiconductor manufacturers are in varying phases of developing immersion production processes and preparing for immersion volume production. We are reiterating our Buy rating on the shares of ASML.
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649 .
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2677 .
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4582 .
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
For More information contact:
Zacks.com
Mark Vickery
312-265-9380
Visit: www.zacks.com
Would you like to see your news and articles here? GO>>
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Investorideas.com® or any of the industry sector portals cannot assure accuracy of the research presented. Investors are encouraged to research and verify facts and under no circumstances is Investorideas.com® endorsing the content as a recommendation to buy or sell stock.
|
